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Abstract
Nature o f the problem: Medication non-adherence is consistently the most frequent cause of 
mental health decompensation, relapse of mental illness, and hospitalization. The solution to 
non-adherence remains quite elusive, despite it being relatively easy to identity as the most major 
obstacle to successful control of mental illness.
Method: Eighteen documents published between years 2002-2012 were rated using the AACN’s 
evidence leveling system. The 18 studies were examined to better understand what is known and 
not known about the challenge we face in trying to effect recovery and to prevent relapse of 
mental illness in the United States.
Results: Various study designs, diverse interventions and treatment strategies demonstrated 
limited success in effecting sustained adherence. However, to date, the literature does not show 
there to be a single, simple, intervention that is effective. The evidence strongly suggests an 
interdisciplinary approach, using various combinations of interventions is the best strategy, but 
not a guarantee. A Power Point presentation was used to share the findings of this project with 13 
PMHNP students and 2 active, expert PhD, PMHNPs.
Nursing implications: Adherence is a complex, multi-determinant, individualized process that is 
embedded in the core belief of the person. Nursing can use this knowledge to collaboratively 
work with patients, their families, and other health care team members to devise approaches to 
facilitate recovery and understanding of the role of medication adherence in recovery 
maintenance.
Keywords: adherence, non-adherence, serious mental illness, compliance
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Medication Adherence: To Have is to Hold
Serious mental illness (SMI) has been defined as, “a mental, behavioral, or emotional 
disorder (excluding developmental and substance use disorders) resulting in serious functional 
impairment which substantially interferes with or limits one or more major life activities” 
(National Institute of Mental Health [NIMH], 2012). The prevalence of SMI in the United States 
is approximately 4.5percent (NIMH, 2012). In 2002, the total annual cost burden of serious 
mental illness in the US was 317 billion dollars (excluding individuals impacted by 
homelessness, co-morbidities, prison incarceration, and early mortality): 100 billion for health 
care expenditures; 193 billion in estimated loss of earnings; and 24 billion in disability benefits 
(Insel, 2008). Clearly, SMI is a very large and very persistent national problem. In 1992, the total 
economic burden was 156 billion. The figures for 2012 portend to be consistent with the growth 
trajectory of the previous decade (Insel, 2008).
As families, health care facilities, health care providers, state, local, and national policy 
makers, and legislators grapple with where and what to cut in order to bring fiscal budgets in line 
with current economic realities, the challenge to adequately care for those with SMI becomes 
ever more difficult. For decades, there has been much thought, talk, and research with regard to 
how to reduce costs in mental health care. There is essentially unanimous agreement across the 
spectrum of mental health care that relapse prevention is arguably the most important and most 
effective cost cutting measure available. Research clearly shows that the problems of relapse and 
failure to achieve recovery are multi-determinant (Lehner et al., 2007; Valenstein et al., 2011; 
Velligan et al., 2010b ). There are major disconnections in the complex system wherein mental 
health care service and health promotion intersect with the client’s personal commitment and 
perceived sense of responsibility to actively work to maintain his/her mental health. Despite the
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tremendous advancement and availability of evidence based psychosocial therapies and an 
abundance of improved psychiatric pharmaceutical agents, medication non-adherence remains a 
monolithic impediment to recovery (Lehner et al., 2007; Velligan, 2009; Weiden, 2007). 
Research has consistently borne out the fact that medication and treatment non-adherence among 
patients with SMI can and do lead to very grave consequences on many levels (Lehner et al., 
2007; Velligan et al., 2010b). Medication non-adherence among individuals with SMI remains 
high for inpatients and outpatients, which in turn, directly and indirectly influence economic 
costs (Lehner et al., 2007).
Purpose
Even with the advent of second-generation antipsychotic medication (SGA), and their 
improved side-effect profile, research shows most patients to have drifted away from compliance 
within one year. 20% to 30 % of clients with schizophrenia never even begin treatment upon 
being discharged from the hospital; 14% to 32% drift away from treatment within 3 months, and 
between 66% to 72% have completely discontinued compliance within 2 years (Cook et al., 
2008). The fact that most people with SMI do actually benefit from antipsychotic medications 
has been thoroughly vetted over the decades (Corrigan, 2002; Lang et al., 2010 Lehner, et al., 
2007; Weiden, 2007) would seem to present the most convincing argument for adherence. 
However, this is not the case; at least, it is not the case for long enough periods for many of those 
who actually suffer with SMI and their families.
Given that we know treatment non-adherence is the single most common reason for 
relapse or recurrence, it seems appropriate that there be a persistent call and cry for more­
concentrated efforts at formulating specific strategies focused on effective ways to promote 
medication/ treatment adherence in individuals with SMI. This treatise proposes to investigate
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the causes of medication/ treatment non-adherence in patients with serious mental illness (SMI). 
This will be accomplished via a thorough review of the current literature to highlight knowledge 
gaps related to the question of why non-adherence is so persistently prevalent in this population. 
It is hoped that uncovering answers to the question will lead to credible hypotheses that might be 
tested in future studies in order to yield effective strategies, therapies, and interventions to 
specifically improve medication and treatment adherence, as well as, to generally break the cycle 
of hospitalization, non-adherence, relapse, and hospitalization.
Significance
Research shows that treatment non-adherence is strongly associated with an increased 
risk for hospitalization (Corrigan, 2002; Lang et al., 2010). The vast majority of psychiatric- 
mental health inpatients require re-hospitalization within two years of their previous inpatient 
admission, due to relapse, secondary to failure take prescribed medications (Vuckovich, 2010). 
The author further states that one-third to one-half of those relapse cases will be involuntarily 
committed with increased disability and serious symptoms such as active psychosis and 
threatening behaviors toward themselves and others (Vuckovich, 2010).
For the purposes of operationalization for research and use to measure patient adherence 
has been quantitatively defined as, taking at least 80 percent of prescribed medication doses 
(Pratt, et al., 2006; Valenstein et al., 2011; Velligan et al., 2010a). There is consistent reminder 
throughout the literature that the issue of non-adherence is complex and multi-determinant. Some 
of the common factors impact adherence are: attitudes and past behaviors; co-morbidity and 
symptom severity; demographic factors; medication-related factors; cognitive impairment, 
family and social support; relationship factors; factors related to the service delivery system; and
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the patient’s perception of stigma; (Corrigan, 2002; Donohoe, 2006; Velligan et al., 2010a; 
Velligan, 2110b; Vuckovich, 2010).
Serious mental illness occurs in all populations and cultures across the lifespan (Vacarolis 
& Halter, 2010). Unlike periodic somatic illness or disease, which might impair or disable a 
specific bodily function or set of related functions, SMI has the potential to cast a very broad 
web of chronic impairment and dysfunction over all dimensional aspects of the individual 
person. Vacarolis and Halter state that SMI tends to be “recurrent or chronic” (2010, p. 678). We 
can logically conclude that the lives of individuals with SMI and the lives of their significant 
others, are frequently and chronically stressed. Clearly, this is a problem which reaches across 
every socio-economical and every cultural divide. This is a dilemma which affects each of us in 
ways which may not be fully realized yet. This is a national problem which will require each of 
us to resolve.
Theoretical Framework
The Psychiatric Mental Health Nursing Scope & Standards of Practice (American Nurses 
Association, 2007), specifically in standards 5E through 5G, commits and dedicates the 
psychiatric mental health nurse practitioner (PMHNP) to channel his/her knowledge, will, 
resources, and goodwill in effort to facilitate achieving the most optimal state of wellbeing 
possible for the individual client/patient. This writer’s personal conviction regarding the elect 
mission of nursing is capsulized as follows: Nursing is all about positively altering the dynamic 
of human suffering. Relief of human misery is a worthy aspiration on any level, in any form, or 
in any context. The nursing profession’s core mission is bound to and invested in recognizing 
and respecting the dignity and inherent worth of each individual. I understand its principal aim to 
be: to intelligently and compassionately serve, advocate, demonstrate, educate, collaborate,
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investigate, and urge to legislate in effort to ensure that each individual can gain maximum 
access to the maximum opportunity to realize his fullest potential in every dimension of 
wellness. Striving and working to heal, to prevent, and to minimize the ravages of mental and 
emotional pathology is the avenue through which psychiatric and mental health Nurse 
Practitioners exert their talents and gifts in effort to contribute to the forward progress of the 
journey of life. These standards and a personal belief regarding the core mission of nursing are 
salient factors which make the Theory o f Self-Efficacy a timeless, and therefore, most-relevant 
framework from which to approach the idea of understanding and transforming the massive 
epidemic that is non-adherence to antipsychotic medication.
Dr. Albert Bandura said, “The value of a psychological theory is judged by three criteria. 
It must have explanatory power, predictive power, and, in the final analysis, it must demonstrate 
operative power to improve the human condition” (Bandura, 2004, p. 628).
The theory of self-efficacy declares that people can change. In 1977, Bandura published a paper 
titled, “Self-Efficacy.” Over the past 30 years, the concept of self-efficacy has had a profound 
and widespread positive effect on the lives of people and institutions. Bandura’s operating core 
belief is that human beings can change; however, he knew and demonstrated that in many 
instances we need help and direction in order to transform mere emotional or cognitive whims 
about change into new, positive, active adaption (Bandura, 2004).
Dr. Bandura defines self-efficacy as: an individual’s belief about his capability to make 
decisions to take actions that exercise influence or control over one’s life. Clearly, we are not all 
equally bathed and nurtured in experiences which allow us to be fully endowed with ample self- 
efficacy. Some of us have more, others have less; however, what Bandura seeks to imprint upon 
us is, each of us can develop or improve our capacity of self-efficacy.
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He reasons four main mechanisms to facilitate the development of a strong sense of 
efficacy. The most effective route is through mastery experiences. There is no argument that 
successful experiences at anything breeds and builds confidence in one’s efficacy. Clinicians and 
care providers should continuously seek out effective means to expose and to educate the non­
adherent patient with regard to the basic utilitarian benefits of recovery.
Bandura (2004) states a second way of developing and strengthening beliefs of personal 
efficacy is through social modeling. The idea being, we learn from each other in all sorts of ways 
and in every kind of circumstance. Frequent, positive, effective exposure to others who have 
successfully adapted adherence to their normal life activity can be a powerful social modeling 
experience for patients with SMI. It is not enough to simply be in the presence of the models, the 
individual struggling with adherence needs to be able to meaningfully engage and interact with 
said models. Clinicians and providers should continuously seek out realistic and effective 
strategies to accomplish this.
The third way of bolstering an individual’s belief that he has what it takes to succeed is 
through social persuasion (2004). When one is encouraged and has confidence in the source of 
encouragement and confidence in the essence of the message behind the encouragement, he is 
willing to try harder or try longer. This is the reason which underpins the recommendation by 
Velligan et al. (2010b) that clinicians and care providers focus on appropriately improving and 
expanding the therapeutic alliance with the patient struggling with adherence. Bandura says, 
much more is involved in the social persuasion process than simply expressing faith in the 
individual’s capabilities (2004). The social persuader is empathetic and acts in the best interest of 
the struggling individual. The social persuader seeks to facilitate opportunities for individuals to 
be successful. Clinicians and care providers can maximize on this intervention through building
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sound rapport which can facilitate the development of strong, effective, therapeutic collaboration 
between the mental health care team and patients.
The fourth way Bandura believes self-efficacy is strengthened is by listening to their 
physical and emotional states. Mood and affect are dynamic domains which play a very large 
role how individuals navigate the day-to-day challenges of life. Bandura states, efficacy beliefs 
exert a very powerful influence on cognitive, emotional, motivational, decision-making 
processes (2004). We constantly measure how experiences make us feel, think, and react. Many 
times, individuals desperately need medication assistance in order to regulate, and to temper 
mood and affect. The major challenge to the PMHNP and other care providers is maintain 
effective and thorough assessment of the patient’s belief and attitude about medication and its 
role in the overall recovery process.
The Theory o f Self-Efficacy is well suited to many interventions designed to promote and 
maintain mental health recovery. The theory continues to demonstrate its relevance and 
applicability in helping individuals to break new ground, to reach new heights in personal and 
professional endeavors. It is this writer’s perspective that the concept of self-efficacy flows in 
conformity with the axiomatic reality that some life changes can only be realized if and when the 
individual living the experience decides to allow it.
Definitions
Medication compliance is a politically incorrect term when one means adherence. Compliance is 
the accurate term to be used for patients in involuntary settings and coercive influence is the 
main determinant of why they are taking medications (Vukovich, 2009).
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Serious mental illness (SMI) is defined as “mental, behavioral, or emotional disorder (excluding 
developmental and substance use disorders) resulting in serious functional impairment which 
substantially interferes with or limits one or more major life activities” (NIMH, 2012). 
Medication adherence is the degree to which patients take medication as prescribed by 
healthcare providers (Donohoe, 2006; Velligan et al, 2009).
Review of Literature
The AACN grading tool (Armola et al., 2009) criteria was used to grade levels of 
evidence presented in the articles and studies used in this project. These levels of evidence 
include:
Level A -Meta-analysis of multiple controlled studies or meta-synthesis of qualitative 
studies with results that consistently support a specific action, intervention or treatment; 
Level B -Well designed controlled studies, both randomized and nonrandomized, with 
results that consistently support a specific action, intervention, or treatment;
Level C -Qualitative studies, descriptive or correlational studies, integrative reviews, 
systematic reviews, or randomized controlled trials with inconsistent results;
Level D -Peer-reviewed professional organizational standards, with clinical studies to 
support recommendations Theory-based evidence from expert opinion or multiple case 
reports;
Level E -Theory-based evidence from expert opinion or multiple case reports;
Level M- Manufacturers’ recommendations only (Armola et al., 2009, p. 72).
In addition, The Agree II Instrument (Agree II Next Consortium, 2009) was used to render an 
evaluation or rating of the quality and reliability of any practice guideline presented in the 
project.
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Types of Treatment Interventions
There are many reasons for non-adherence to psychotropic oral medication such as, 
inability to afford the cost, a belief that medication is not needed, poorly understood instructions, 
medication side effects, quality of patient/provider relationship, and various others (Haynes, 
2012; Donohoe, 2006; Velligan et al., 2009; Velligan, 2010). Whatever the reasons for non­
adherence, a realistic, achievable solution must be developed to help interrupt the well-worn 
cycle. The very alarming, aforementioned statistics demand that an answer be found, discovered, 
or created. The hope and expectation of this review process is that insight gained will to lead to 
new ideas and efforts which helps bridge the expanse between the known and the unknown with 
regard to interrupting non-adherence and facilitating adherence.
The 18 studies selected for review, investigated a variety of interventions aimed at 
promoting and enhancing adherence to psychotropic medication in populations with SMI. Each 
study was laid out on a grid-like evaluation matrix and arranged to allow a visual contrasting of 
authors, design, methods, sample size, data analysis findings, and other elements of the studies. 
Treatment intervention groups of the various studies were compared to the “usual care or usual 
treatment” control groups. The diverse types of interventions being tested included pharmacy- 
based interventions (Valenstein et al., 2011; Sajatovic et al., 2007; Lang et al., 2010), 
interventions which investigated age differences and its effect on adherence (Pratt, et al., 2006; 
Lang et al., 2010), outpatient, intensive case management interventions (Van Dorn et al., 2010; 
Rotondi et al., 2010; Dixon et al., 2009; Pratt et al., 2006), telemedicine and electronic 
monitoring interventions (Cook et al., 2008; Rotondi et al., 2010), cognitive behavioral therapy 
as a direct intervention (Donohoe, 2006), motivational interviewing (MI) as measurable 
intervention (Corrigan, 2002), differences in provider/patient relationships, as an intervention
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(Sajatovic et al., 2006), and an intervention in which specific registered nursing teaching is the 
measurable treatment (Cooke, et al., 2008). This writer will discuss the literature and findings 
from the context of the design method or type of study each work is. The designs are as follows: 
systematic/integrative reviews, RCT/non-RCT, guidelines, retrospective studies, correlational 
studies, cross-sectional study, and structured interviews.
Systematic/integrative Reviews
There are four articles in this category. Two are meta-analyses (Haynes et al., 2012; 
Velligan et al., 2006), and two are integrative reviews of literature (Corrigan, 2002; Donohoe, 
2006) with qualitative analysis. Each review contributed important substance and deepend the 
well of knowledge regarding the serious implications of non-adherence and proposed thoughtful 
ideas for future, testable interventions. Haynes et al. (2012) conducted a meta-analysis and 
review using a qualitative analysis of 78 unconfounded RCTs with the express purpose of 
discovering what is known and what is not adequately understood about self-administered 
medication adherence. Velligan et al. (2006) reviewed a total of 161 articles that specifically 
involved populations with SMI and interventions aimed promoting adherence or gaining better 
understanding of non-adherence issues. The mission of both was to not only get a clearer picture 
of the current state of adherence in general, but to also consider the gradations of adherence 
(partial, minimal, or full) in individuals.
The Haynes et al. (2012) review included RCTs which used interventions across the 
range of medical and psychiatric disorders, and across demographic characteristics. The only 
condition excluded was addiction disorders. The Haynes et al. (2012) review was not exhaustive; 
nevertheless is was very thorough. The review divided the RCT interventions in long term 
(greater than six months) and short term (less than sixmonths) interventions. The various
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features and instuments of each study was compared and the results carefully looked at for 
similarities and differences in outcomes. Ultimately, both reviews concluded that simple 
interventions were not effective, and a few longterm and/or complex interventions were 
effective. The review affirmed what many studies have: non-adherence is multi-determinant and 
complex (Haynes et al., 2012; Velligan et al., 2006). The findings speak to non-adherence 
presenting the very same dynamic challenge regardless whether the disorder being is medical or 
psychiatric. Both studies rate level A per the AACN evidence rating scheme.
The study by Corrigan (2002) is very interesting, in that it attempted to investigate the 
issue of adherence/non-adherence through the prism of health behavior theories (HB) and the use 
of motivational interviewing (MI). The central idea behind HB theories has to do with cognitive 
and interpersonal factors which have much to do with the decisions and actions human beings 
engage in to protect and maintain health. While MI was designed for and successfully used to 
effect positive outcomes in treating substance abusers, and it recently had been applied to other 
psychiatric disorders (Corrigan, 2002). He posited the premise, MI could be used to help clarify 
or enhance value expectancy (the perception of the cost and benefit of a disorder).
Corrigan highlighted the importance of committed, informed, and well-coordinated social 
support (total interactions in SMI client has with health care providers and family support), and 
thereby increase the likelihood of adherence in the client (Corrigan, 2002). The literature shows 
that there are various levels of barriers to adherence: client barriers (lack of disease awareness, 
cognitive deficits, sense of disempowerment, medication side effects) and social support barriers 
(poor partnership alliance between mental health system and client; a family/significant other 
system that is not actively engaged in promoting the value of adherence; a lack of resources or 
support for client; family/ significant others lack information or understanding of importance of
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continued adherence for the long-term). Dr. Corrigan proposes that the greater portion of these 
barriers can be reduced or dismantled through MI and other empirically validated intervention 
strategies (Corrigan, 2002).
In 2006, Donohoe also delved into a study which attempted to look at the “world’s other 
drug problem” (non-adherence) from a cognitive behavioral perspective. He was particularly 
interested in RCT investigative studies done by Kemp in the late 1990s on “compliance therapy.” 
The initial study and the subsequent 18 month follow up study showed that knowledge and 
insight had significantly inproved, but also drug attitudes, and adherence had improved—that is, 
time between readmission and relapse had increased in the treatment intervention group. Both 
studies show promise of helping to diminish the adherence gap and being more cost effective 
than the usual treatment. However, both studies also have similar limitations: relatively small 
study samples, and the cognitive and social dysfunction patients with SMI often face (Corrigan, 
2002; Donohoe, 2006).
Donohoe (O’ Donnell et al.) and his own investigation team attempted to successfully 
duplicate the Kemp study. The initial part of the RCT went exactly as it had for Kemp; however, 
the follow up study failed. In addition to other smaller differences, the O’Donnell et al. trial’s 
assessment of compliance was conducted blind to treatment, whereas the compliance assessors 
in the Kemp et al. study were not blinded (Donohoe, 2006). Both studies conclude, while there 
is promise that cognitive behavioral therapies can be helpful, there is no evidence that these 
interventions alone could exert a positive effect on adherence. The work by Dr. Corrigan was 
very interesting and offered multiple suggestions for further hypotheses and research. While it 
was not study which tested interventions, it proposed several evidence-based strategies for using
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Motivational Interviewing to enhance value expectancy and social support in the client with 
SMI, health care professionals, and the client’s family/significant others.
As shown by divers types of other studies (Lehner et al., 2007; Velligan et ah, 2009; Weiden, 
2007) designed to understand the complexities of adherence. They too recommend a multimodal 
approach to adherence treatment (Corrigan, 2002; Donohoe, 2006).
RCT/Non-RCT Studies
There are six studies in this design category. Cook et ah, 2008; Pratt et ah, 2006; and 
Valenstein et ah, 2011 used pharmacy-based interventions in which the treatment group received 
direct supervision, assistance, and education in connection to medication usage. Each 
investigation was well designed and controlled for multiple variables. The Cook et ah (2008) 
trial was a non-randomized study and used RNs to administer the treatment to the intervent ion 
group over the telephone. Registered pharmacists administered the treament to the intervention 
group in the Valenstein et ah (2011) study; however, training and qualification of those 
administering treatment in the Pratt et ah (2006) trial is unclear. Each study was aimed at 
discovering whether its respective intervention would reduce emergency department (ED) use, 
increase medication adherence, increase knowledge, improve cognitive measures and clinical 
functioning, and decrease symptoms and relapse in people with SMI vers compared toSMI 
patients receiving the usual care. A varity of measures were used to assess medication adherence 
such as, self and informant reports, an attitude toward medication rating scale, pill counts, 
pharmacy fill/refill data, and medication porsession ratios.
The treatment group in each study was well below 100 participants and therefore reflect a 
limiting of sample power. The three pharmacy-based trials collectively covered a wide range of 
ages (18 & older) as well as a sizable swath of demographic diversity. The sample pools
Medication Adherence 16
included patients from medicaid health plans (Cook et al., 2008), Veteran Affairs (Valenstein, et 
al., 2011), and community mental health centers (Pratt, et al., 2006). The time period for the 
application of the treatment interventions ranged from six to twelve months in addition to six to 
twelve months of follow up data collection. Various tools were use to analyze the data gathered 
from the respective studies. Cook et al. (2008) used SPSS 15.0 and ED visit data and MPRs;
Pratt et al. (2006) employed the use of more than 10 different tools and assessment scales collect 
and decipher its data; and Valenstein et al. (2011) used MPRs, “composite adherence measure” 
(CAM), PANSS, intraclass correlation effeciencies (ICC), logistic regression, multivarate, and 
multiple linear regrssion analyses to quantify and interpret data. The sample size of the study by 
Valenstein et al., (2011) was less than ideal for extrapolating the results to the general population 
of persons with BPD. The relatively narrow age range of the cases in the registry limits the study 
by Sajatovic et al., (2007) in the same manner.
Both studies employed appropriate tools to exact a rigorous analysis of data yielded. Both 
studies produced results similar to previous research. Important implications for the mental- 
health, clinical practice setting can be drawn from each study. The study by Cook et al. (2008) 
was non-randomized. While it yielded useful evidence, it had multiple structural problems, 
which limited its generalizability and subjected it to bias from several angles. The results were 
similar for all three studies: MPR and knowledge of medication (and illness, where applicable) 
improved; however clinical symptoms and functionality was unchanged, neither was there any 
significant change in relapse tendencies.
The remaing three studies each used an intensified case management-type intervention as 
the investigative treatment. The interventions involved thorough pre and post treatment 
assessment of the the intervention and control groups. The treatment interventions engaged the
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patients in very structured educational sessions on illness, relapse prevention, medication 
adherence, and overall treatment collaboration as a part of the recovery process. RNs and social 
workers, and other trained clinical staff were effectively used in the conduction of the studies. 
Dixon, et al., 2009; Rotondi, et al., 2010; and Vreeland et al., 2006 are RCTs with treatments 
designed to examine whether the intervention would improve knowledge of illness and 
medication, decrease ED use, increase clinical and cognitive functioning, or improve adherence. 
The treatment time for each study was one year, with a follow up data collection ranging from 
six months to one year. Sample participants were recruited from VA centers, with an age range 
18-70 (Dixon et al., 2009), a state-wide mental health care delivery system, with an age range 
from 18-70 (Vreeland et al., 2006), and from community mental health centers and inpatient 
facilities, with a patient age range from 14-70 and a support person age range from 18-70. The 
same study also directly included significant others who were support persons to the patients as 
randomized sample participants (Rotondi et al., 2010). The size of the treatment groups of each 
study was much less than 100 and is determined to be a limitation of the study.
Each study concluded that intensive, case management-type intervention showed 
promise as each of the various interventions resulted in significant efficacy compared to the 
usual treatment with respect to the primary outcomes of knowledge of illness, medications, and 
increased awareness of rising crises. However, neither had significant effect on secondary 
outcomes such as clinical and cognitive functioning, symptoms, or medication adherence overall 
(Dixon, et al., 2009; Rotondi, et al., 2010; and Vreeland et al., 2006). The studies were well 
designed with controls and randomized treatment of the samples. They were powered to render a 
verdict as to the effect of the treatments on the primary and secondary outcomes. Each
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investigative study in this design category merited a level B evidence grade according to the 
AACN grading standard.
Treatment Guidelines
Two pertinent works (APA, 2004; Velligan et al. 2009) were selected for inclusion in this 
design category, and therefore added to the article evaluation matrix as part of this project’s 
literature review because they each self desribe as guidelines. They are both completely invested 
in recommendations for either the usual care, or for new interventions to treat patients with SMI. 
The American Psychiatric Association’s (APA) 2004 revised practice guideline called, Practice 
Guideline for the Treatment o f Patients with Schizophrenia. This officially published treatment 
guideline is accessible on the APA’s website and is available to assist clinicians and care 
providers in the diagnosing, treatment, and management of care for clients with schizophrenia. 
Treatment guidelines can be found on the the APA’s website for the entire range of mental 
disorders. The composition of the document is informed by the exhaustive computerized search 
of vast bodies of every relevant literature database produced from 1994 through 2002 (APA, 
2004). Essentially every level of evidence is represented in the guideline, as its mission was to 
put forth the most up to date evidence-based knowledge to govern every type and manner of 
therapy and treatment of the disorder. The guideline has much to say regarding medications, the 
efficacy of medications, and the importance of medication adherence to overall maintenance of 
well-being of the client with SMI. The APA guideline is thorough and of high quality evidence, 
however, the current version is eight years old and therefore, is not informed by current 
knowledge and evidence-based standards.
As mentioned earlier, the Agree II Instrument (Agree Next Steps Consortium, 2009), a 
widely accepted tool for methodically and systematically evaluating the quality and reliability of
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evidence presented in practice guidelines, was used to render a quality score for this practice 
guideline. The grading was accomplished by this writer, as the single appraiser, and yielded the 
following scores: Domain 1- Clarity and Purpose, 100%; Domain 2- Stakeholder Involvement, 
100%; Domain 3- Rigour o f Development, 100%; Domain 4- Clarity o f Presentation, 100% 
Domain 5- Applicability, 83%; Domain 6,- Editorial Independence, 92%; and Domain 7- Overall 
Guideline Assessment, 87%.
The second guideline in this category is, The Expert Consensus Guideline Series: 
Adherence Problems in Patients with Serious and Persistent Mental Illness. It was published in 
2009. Its stated goal is to make recommendations for specifically assessing and improving 
adherence in patients with SMI. The project was conceived in face of the devastating 
consequences of poor adherence and non-adherence to treatment for patients (and their families) 
who suffer with SMI, and the great cost burden bom by the United States, as documented earlier. 
An exhaustive search of pertinent literature between the years 1970 to 2006 was undertaken and 
from that review, a survey of 39 questions and 521 optional responses was developed. The 
survey was sent to 48 experts in The U.S., the United Kingdom, and the Netherlands. The 
experts were chosen based on the criteria of having published research on SMI and/or 
participation in previous expert consensus surveys that addressed issues related to the 
management of schizophrenia and bipolar disorder. 41 of the 48 leading experts responded to the 
survey. The response data was compiled analyzed using chi square and confidence intervals to 
establish concensus. Research data and other published findings concerning adherence were 
combined with the survey results to formulate clinically relevant and useful recommendations on 
how to effectively assess, and manage problems with adherence in SMI in order to promote the 
best outcomes for patients (Velligan et al., 2009). This guideline perspectives and
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recommendations is very much consistent with the current professional and expert literature 
regarding adherence/non-adherence. Again, the Agree II Instrument was employed by this writer, 
as the single appraiser, to evaluate the reliability and validity of the guideline, and yielded the 
following scores: Domain 1- Clarity and Purpose, 100%; Domain 2- Stakeholder Involvement, 
63%; Domain 3- Rigour of Development, 79%; Domain 4- Clarity of Presentation, 100%
Domain 5- Applicability, 87%; Domain 6,- Editorial Independence, 92%; and Domain 7- Overall 
Guideline Assessment, 83%.
Retrospective Studies
Three retrospective studies (Gilmer et al., 2004; Lang et al., 2010, & Van Dorn, et al., 
2010) were included in the article evaluation matrix. The three investigations, while pursuing 
very different primary questions, shared seondary and tertiary concerns. A more cohesive and 
thematically connected trail of evidence and thought process emerges as these studies are viewed 
collectively. Each used a large sample of data sets from paid medicaid medical and pharmacy 
claims for services to patients with established diagnoses of SMI (schizophrenia and bipolar 
spectrum disorders). Gilmer et al., (2004) 1,619 claims from California, Lang et al., (2010) 
12,032 claims from the state of Florida, and Van Dorn et al., (2010) 3,576 claims from New 
York.
Almost immediately, one begins to appreciate the potential wealth of geographic and 
demographic factors that might draw interest with regard to the results of each study’s findings. 
The primary objective of each study was: to analyze the relationship between adherence to 
antipsychotic medication and health care costs (Gilmer et al., 2004); to evaluate the rates of 
adherence among patients treated with long-acting injectable and oral antipsychotics (Lang et al., 
2010); and to evaluate the time relationship between the end of involuntary (court ordered)
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outpatient medication treatment and adherence (Van Dorn et al., 2010). Each of the studies 
mined data which was well established and stable. The Van Dorn et al. (2010) study used data 
collected between 1999 and 2007. They used multivariable time-series analysis to compare pre­
court ordered treatment and post court ordered treatment. They also compared MPRs and 
pharmacy fill records to assess adherence. The results of the study showed a clear relationship of 
conformity between the length of court ordered medication treatment period and the amount of 
time, after the court ordered treatment ends, until pharmacy refills begin to decrease. In other 
words, the longer the court ordered medication treatment period, the longer it takes non­
adherence to manifest itself (Van Dorn, et al., 2010).
Lang et al. used data collected by Florida medcaid between July 2003 and June 2006. 
They used MPRs to assess medication adherence; however, they also looked deeply into the 
specifics of individual degrees of adherence (or non-adherence) by analyzing medication 
persistence, medication consistency, and maximun gap in treatment. They employed reliability of 
Multivariate logistic regression models to identify predictors of hospitalization and non­
adherence. Their findings are very consitent with the results of similar studies in this population 
with regard to medication nonadherence tendency: younger more than older, males more than 
females, minorities more than whites, substance users more than nonusers, and multiple axis I 
diagnoses more than a single axis I diagnosis. They also report patients who received long-acting 
first-generation antipsychotics (FGA) showed greater tendency toward non-adherence; whereas, 
patients who received long-acting second-generation antipsychotic (SGA) or a combination of 
both, showed less tendency toward non-adherence (Lang et al. 2010).
Gilmer et al. (2004) merged California state medicaid data and San Diego County Adult 
Mental health Services data from 1998 to 2000 to address the primary question of its
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investigation. As mentioned in the introduction, the economic burden (and how non-adherence 
intensifies and greatly complicates an already very difficult crisis) of caring for SMI patients in 
the U.S. is very great and very complex (Insel, 2008). The authors of the study wanted to try to 
quantity what the cost of individual adherence or non-adherence might look like. They used 
pharmacy fill/refill records, and MPRs to assess medication adherence, as was done in the other 
studies in this category. They also used logistic regression model analysis to estimate the 
tendency of the various groups (adherent, partially adherent, non-adherent, and excess fillers) 
toward adherence. They conducted a post hoc analysis and logistic regression to address the 
finding on excess fillers, in particular.
The findings of this study were consistent with the findings of the two (Lang et al., 2010; 
Van Dorn et al., 2010) other retrospective investigations. Gilmer et al. (2004) found that 41% of 
the sample were adherent with their precsribed antipsychotic medication regimens; 24% were 
non-adherent; 16% were partially adherent; and 19% were excess fillers. Psychiatric 
hospitalization rates were 14% for those who were adherent; 35% for those who were non­
adherent; 24% for the partially adherent; and 25% for those who have excess refills. Medical 
hospitalization for excess fillers was 12%, while the medical hospitalization rate for those who 
were non-adherent was 13%. The total pharmacy costs for excess fillers of medications were 
substantially higher than the total cost of any other group. In looking at excess fillers in more 
detail, the study found that minorities were less likely to be a excess fillers than whites; 
individuals in assisted living facilities were more likely than those living independently to be 
excess fillers; and receiving multiple antipsychotic medications was strongly related to the 
probability of being an excess filler of medication (Gilmer et al., 2004). The retrospective 
analysis by Lang et al. (2010) affirmed some of the results of various studies over the past
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several years, which speak to the association between older age, SGA medication, combination 
therapy, and decreased likelihood of non-adherence. The study also associated younger age, 
substance abuse, and use of medications to treat comorbid mental illnesses with increased 
likelihood of repeat hospitalizations and non-adherence. The study limitations included it offered 
no interventions or control for the vast differences among demographic features.
The authors concluded, despite the widespread use of SGA, adherence to treatment 
remains a very significant problem. The study’s findings with regard to adherence and the 
statistical predictors of non-adherence appears almost identical to the findings of similar studies 
(Gilmer et al., 2004). Each of the studies in the retrospective design rated level C per the AACN 
evidence leveling system.
Correlational Studies
Polit and Beck (2012) describe a correlational design as research which investigates 
relationships among variables of interest without introducing a research intervention. There is 
but a single article in the evaluation matrix from this design category. Sajatovic et al. (2007) 
conducted a correlational study to evaluate antipsychotic medication adherence among older 
versus younger individuals with bipolar disorder (BPD). The study sample was a large case 
registry (the VA’s National Psychosis registry) of over 73,000. The authors wanted to see what 
effect age might exert on medication adherence among individuals with SMI. The medication 
possession ratio (MPR) was again, the basic quotient used to measure adherence. The age 
demarcation was 60 years. The group under 60 had a median age of 47 and the group over 60, 
the median age was 69.5. The study spanned a 12-month period. The MPR scoring was measured 
in degrees: fully adherent (> 0.8), partially adherent (> 0.5), or non-adherent (< 0.5). The results 
show, the over 60 group maintained a higher MPRs than the under 60 group. The study has
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strengths and weaknesses of similar studies done previously. The Sajatovic, et al (2007) study 
was well-designed. It analyzed a large amount data which resulted in indications that there is 
clearly a relationship between age, combination therapy, and medication treatment adherence. 
According to the AACN leveling system, this study is rated level C evidence.
Cross-sectional Studies
The article evaluation matrix contains a single cross-sectional study. A cross-sectional 
design is a research study in which data is collected at a certain point in time and is observed and 
analyzed for relational clues and patterns (Polit & Beck, 2012). Cross-sectional studies are more 
broadly classified as descriptive studies, in that thery are used to make observations and to 
describe relationships. Sajatovic et al. (2006) conducted a cross-sectional study using data 
collected over a four year period (1997-2000). The final sample consisted of 184 veterans from 
11 different VA centers around the country. Each participant had been a part of an earlier study 
done by the Department of Veterans Affairs in order to collect data to help focus thinking (at the 
time) with regard to how to more effectively treat and manage bipolar disorder. Sajatovic et al. 
(2006) essentially inherited a ready-made sample. Each of the paticipants had an established 
diagnosis of bipolar disorder. The objective of the study was to analyze the sample group for 
patient characteristics, the dynamics of the individual patient-provider relationships, and barriers 
to care in the context of self-reported treatment adherence.
The analysis began by dividing the sample into two groups, adherent (N—113) and non- 
adherent{N=71), based on self-report and confirmed by patient characteristics data from the 
previous study. Sajatovic et al. (2006) had constructed several hypotheses prior to looking at any 
of the data:
We hypothesized that specific features would be related to better treatment adherence:
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patient characteristics (fewer symptoms, overall better health status, higher functional 
level, female gender, and absence of substance use disorder), features of the patient 
provider relationship (better treatment alliance, fewer medications, and minimal 
medication adverse effects), and minimal or no barriers to treatment access (Sajatovic et 
al., 2006, p. 57).
A large battery of assessment tools were employed gather the data in the original study:
Structured Clinical Interview for DSM-IV (SCID), Global Assessment Scale (GAS), 
Somatotherapy Index, Side Effects Summary, Patient Satisfaction Index, and several others.
Chi square tests and pooled T tests were used to analyze and compare the differences between 
the to groups. The cross-sectional study team affirmed only one of their hypotheses: indeed 
substance use exerts an opposing force on adherence tendency in bipolar patients. However, 
the same could not be said for a prior history of substance use. The study authors found 
characteristics of the patient-provider relationship and the role of co-morbid conditions had a 
greater effect on adherence than the other factors mentioned in their hypothesis. These finding 
are not inconsistent with the findings of similar research (Sajatovic et al., 2008). The authors 
speculate that some of the limitations of the original study may be related to specific processes of 
healthcare delivery with the VA system (Sajatovic et al., 2006). Nevertheless, the larger import 
of the findings of the cross-sectional analysis is that adherence is not unidimensional, multi­
determinant. The study also clearly illustrates the necessessity that clinicians and providers 
continually assess for avenues to strengthen the therapeutic alliance with patients and their 
support persons. The AACN evidence leveling system rates this cross-sectional study at level C.
Semi-structured Interviews
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Roe et al. (2009) conducted an interesting qualitative study to explore why and how 
individuals with SMI engage the process of choosing to discontinue taking prescribed 
medications. The data for the qualitative analysis was collected via the format of a semi- 
structured interview. The participants of the study were recruited through newspaper 
advertisements and internet forums. The total sample consisted of seven adults with a 
schizophrenia or bipolar spectrum disorder. Each of the four women and three men had 
volitionally and fully stopped taking their medication for at least one year.
Each participant took part in a 90 minute, in depth semi-structured interview conducted 
by a tandem of a graduate psychology and an undergraduate psychology student who had been 
trained to conduct narrative interviewing. Each of the interview sessions were recorded and 
transcribed. The participants were asked to share their personal stories regarding how and when 
they were diagnosed with mental illness. They were asked to share their medication history and 
how and what their beliefs are regarding medication as a therapy or treatment and how they 
personally responded to the treatment (Roe et al., 2009). The interview process was structured to 
elicit the most complete subject expression of the participants’ view and perception of 
medication therapy of their illness and on there lives.
Analysis of the data laid the ground work for the development of a “hypothesized” model 
of the process involved in deciding to no longer take medication. The authors presented the 
hypothesis as a five-stage process: Stage 1—The Person Experiences a Major Emotional Crisis;
Stage 2—The Subjective Experience o f Taking Medication and Its Consequences; Stage 3—The 
Conflict: To Adhere or Not to Adhere?; Stage 4—Gradual Resolving o f Conflict; and Stage 5— 
Developing a Personal Perspective on the Use o f Medication (Roe et al. 2009). This study is 
very small and therefore very limited in its power to be generalized to the larger population.
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However, the results and findings of this qualitative analysis is very similar to the finding of 
related studies. Non-adherence is not one dimensional; it is not either black or white; instead, it is 
complex with multiple determinants (Velligan, 2010; Sajatovic et al., 2008). The results of the 
study strengthens the need for further investigation to understand the layers of subjective 
perception (core belief) which form the basis of adherence. Attitudes and beliefs can and do 
change therefore, the clinician and patient (the therapuetic alliance) can be the beneficiary of a 
nonjudgmental interview to assess and discuss the patient’s beliefts about health, including 
adherence to medication can be incorporated in the overall discussion of other health promoting 
behaviors, life goals and plans to work on bein as healthy as possible (Wieden, 2007). This 
article is rated level C evidence per the AACN grading system.
Methods
Literature published between 2002 and 2012 was searched using well-known major 
words (and their variations) as a starting point to search for related articles and studies 
concerning treatment adherence in mental illness. These well-known words included medication 
non-adherence, medication noncompliance, serious mental illness (SMI), mental illness, mental 
disorders. Using the PubMed database’s MeSH search, with the limits of adult, English 
language, and published in the last 10 years yielded 150,587 items for mental disorders (search 
#1), 2105 items for medication adherence (#2). A general PubMed search (with the same limits) 
yielded the following: 3401 items for serious mental illness (#3); 4725 items for medication non­
adherence (#4); 4777 items for medication noncompliance (#5); combined search #1 and #3 to 
yield 3205 items (#6); combined #4 and #5 to yield 4652 items (#7); finally a search combination 
of #3 and #4 yielded 23 items.
The same limits and process was used to search the CINAHL and PsychINFO
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databases. After various combinations of limits and key-word searches, the yield narrowed to 21 
and 24 research articles. The Cochrane Library was searched using the same terms and various 
combinations of the terms. Limits were set to Cochrane Reviews and publication between years 
2002-2012. Search for terms serious mental illness and treatment adherence (#4) yielded 238 
records; 215 records for medication and treatment adherence and serious mental illness (#3); a 
search using the key words, treatment non-adherence and serious mental illness produced 30 
records (#2); and finally a search of the terms, medication and treatment non-adherence and 
serious mental illness yielded 30 records (#1). Each search returned only one record that was 
specifically applicable to the topic of this paper and that item was the first record atop three of 
the lists of results and listed third on the remaining. The record was selected for inclusion in this 
review.
A manual search of the reference list of an article with an extensive review of works on 
treatment non-adherence in the seriously mentally ill was also conducted. The combined 
computer database and manual searches resulted in 38 relevant articles or research studies, and 
one pertinent treatment guideline for review. Eighteen of those studies were evaluated in a 
spreadsheet format, in effort to systematically scrutinize each for the quality of its value and to 
ascertain if it lends any legitimacy or significance to the purpose of this inquiry.
Over the past four semesters, this writer has had many opportunities to speak with and 
listen to Kimberly M. Gregg, MS, PMHCNS-BC, clinical assistant professor at the College of 
Nursing at the University of North Dakota, where she also serves as the co-director of the 
Psychiatric and Mental Health Nursing track. She will soon complete her DNS dissertation. She 
has plied her expertise for more than two decades as a psychiatric mental health clinical nurse 
specialist. As a current, expert care provider, and as academic adviser to this writer, she has been
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a readily- accessible consultant throughout the course of this project. In addition, the findings of 
this project were shared via a Power Point presentation with Dr. Kay L. Foland, PhD, RN, 
PMHNP-BC, CNS-BC and Dr. Virginia S Biddle, PhD, RN, PMHNP, PNP.
Results
Appendix A lists 18 studies selected for review of evidence related to adherence 
behaviors. It compares the type study, the criteria for defining adherence, the method for 
assessing adherence /non-adherence, the sample size, the demographics of the sample, and the 
types of treatment intervention used in the study (if applicable). 22% of the studies were reviews 
of literature which sought to improve the understanding of adherence and the development of 
more effective treatments. One review was a meta-analysis of every kind of adherence 
intervention across all medical and psychiatric disorders (except addiction disorders), another 
focused SMI and various adherence treatments, the other reviews sought to review literature 
which looked at the effect of cognitive behavior and health belief theories as treatment 
interventions. Despite the divergent angles from which the reviews approached the question, the 
finding and conclusions were essentially the same.
33% of the studies included among the review articles are RCT/NRCT investigations. 
Each one investigated the effects of an intervention {Script Assist, Meds Help, BCTI, SOAR, 
MMAA, Team Solutions) designed to improve the patient’s knowledge of his/her diagnosis and 
prescribed medications to see how the change in knowledge might affect the quality and/or 
duration of medication adherence. One of the studies included significant others or support 
persons in the treatment process. The sample sizes were generally less than 100 participants, 
included males and females, diverse ethnicities across the 18-70 age range. 100% of the 
investigations used multiple measures to assess adherence such as, MPR, self-reports, pill counts,
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and others. On average, each study was 12-16 months long, with an additional 6-12 months 
follow up period. The findings were the same despite the variety of interventions: non-adherence 
is multi-determinant, and interventions can be effective, however, they cannot be simple or one 
dimensional.
34% of the studies listed in appendix A are retrospective, correlational, cross-sectional, or 
structured interview designs. Study investigators analyzed state Medicaid or VA center data. 
Sample sizes ranged from 150 to more than 10,000 SMI patients, looking at adherence behaviors 
and practices based on, provider reports, self-reports, pharmacy fill/refill data, MPR, and other 
assessment measures. The findings show consistent results. Multivariable analysis, multi-linear 
regression models, random coefficient regression, and other instruments were appropriately used 
to analyze the various studies to account for the differences in demographic characteristics such 
as age and gender, and to attempt to identify predictors of non-adherence. Despite the varying 
investigative approaches, the diverse treatment strategies, the broad range of demographic 
characteristics, the selection of assessment methods, and the various selections of instruments of 
analysis, the broad findings of the studies were as follows: males with SMI tend to be less 
adherent than females; younger patients less than older; minorities than whites; persons of low 
socioeconomic status less than those of a higher socioeconomic status; and persons with multiple 
axis I diagnoses tend to be less adherent than those with a single axis I diagnosis. These findings 
are very consistent with the findings of similar investigations.
The remaining 11% of the documents evaluated was an official, practice guideline and 
specific, expert recommendations aimed at breaking the cycle of non-adherence. The evidence 
shows that adherence is complex and multi-determinant. It also clearly affirms certain 
combinations of interventions can be effective in improving adherence. 100% of the studies in
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appendix A call for more investigation of complex, longer term treatments. The studies also call 
for design and testing of treatment strategies which focus on enhanced collaborative alliances 
among care providers, patients and supporters, and other interdisciplinary team members.
The question, objective, and findings of this project were shared with 2 active, expert 
PhD, PMHNPs and 13, second-year PMHNP students via a Power Point presentation. Their 
input and commentary was instructive and lead to helpful adjustments in several sections of the 
paper. Each respondent personally affirmed the significance of the problem and the need for 
further investigation and study to find effective treatment to promote medication adherence. 
Each respondent also expressed interest in opportunity to access the full reading of the project.
Discussion and Implications for Nursing
Each study, article, or guideline evaluated lends some degree of validity and affirmation 
of the necessity to more mind power and financial power focused on the gigantic national 
problem we face in medication adherence/non-adherence. One author very aptly characterized 
the problem of adherence as, “the world’s other drug problem” (Donohoe, 2006). The works 
sited each speak to the very real chaos and dysfunction, which SMI deals out to families on a 
daily basis, all across the United States. Each study or body of work reviewed is a valid and 
useful piece of the evidence puzzle that must be used to construct more realistic, effective 
interventions to remedy the predictors of non-adherence. The usual treatment and care approach 
to non-adherence to antipsychotic medication has allowed lives to drain of vitality and many 
families to wane in hope.
Each of the documents in this review in large or small measure contributes to the slowly, 
steadily evolving body of investigative knowledge, which moves us ever closer to the answer 
and remedy to medication and treatment non-adherence in adults with SMI. There is no doubt,
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there is a role for Motivational Interviewing to play in helping health care professionals, family 
members, and individual clients to build effective alliances which function to facilitate the 
objectives of the treatment plan of care in every way. It is clearly conceivable that tele-health 
medication interventions will become a significant part of the solution to effect practice change 
in the ongoing fight to decrease the likelihood of non-adherence behaviors. The results from the 
study by Valenstein et al. (2011) offers valid affirmation that an appropriate process and 
mechanism can be designed to assist clients with better understanding what their medication is 
for and why it should be used precisely as directed. A cost effective program that embodies the 
intent of this intervention would represent a significant practice change, while moving the bar in 
the right direction with regard to dismantling non-adherence. The gaps in knowledge are 
gradually being bridged by new theory and evidence-based strategies for solving problems.
Perhaps, the greatest challenge that blocks the path of liberation from non-adherence is 
the epic struggle that plays itself out daily in the minds of Americans, as to what is the value and 
worth of health care. The country is yet a great distance away from the mind-set that declares 
that every individual’s health is as valuable as any other’s is, and that there is a collective-debt 
that we owe to each other to actively safeguard it as a cherished right. The passage of the 
Affordable Care Act (ACA) moves us a little closer; but there are still many months before it is 
fully implemented. Yes, the allocation of resources, priorities, time, and value is always a great 
and difficult struggle in the most enlightened and wealthiest civilization the world has known so 
far.
Implications for Practice
There is a very clear, very consistent thread of interest for the role of the PMHNP bom 
out in each study, including those which do not appear in the reference list. Mental illness is not
Medication Adherence 33
going to go away. The literature is unanimous in its assessment that medication and treatment 
adherence is not bigger or more pronounced in mental illness than it is in medical illness—it is 
equally epidemic there as well (Donohoe, 2006; Haynes et al., 2012). However, there is no 
medical counterpart that rivals the level of social upheaval and chronic disability that non­
adherence delivers to the young and able-bodied with SMI. The evidence urges clinicians and 
care providers to purposefully engage patients and their support persons on the issue of 
adherence (Donohoe, 2006; Haynes et al., 2012; Velligan, et al., 2010b; Weiden, 2007).
It is this writer’s perspective that there is a pressing need to educate patients and their 
families, but also a need for many care providers and clinicians to assess and evaluate their 
individual understanding and perspective regarding the complexity of adherence. It is much more 
than simply not taking or refusing to take a prescribed medication. Weiden (2007) states, 
viewing adherence and non-adherence as part of navigating the illness-recovery continuum, can 
help reduce and defuse the frequent power struggles between clinician/care providers and the 
patient.
Implications for Research
Research consistently shows non-adherence is multi-determinant and complex (Velligan, 
2010; Velligan et al., 2010b); therefore, it would be useful to call for more studies that 
investigate complex treatment interventions. The evidence also points to a need to for testing of 
interventions that involve support persons playing a more informed role in assisting loved ones 
suffering from SMI. As more PMHNPs become care providers in inpatient and outpatient 
settings, perhaps the growth and expansion of a more holistic perspective will inspire new and 
innovative treatment ideas and interventions.
Implications for Education
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There is no doubt that more care providers will be needed to help care for the millions of 
newly insured patients who are sure to seek out care, once the ACA is fully implemented in 2014 
and the coming years. It is expected there will be a need for thousands more care providers.
There is great concern that there will not be enough primary care physicians to meet the need. 
There is much talk of PMHNPs being readied to help fill the gap, especially in rural or remote 
communities. The plans to make the DNS the entry level for NPs is problematic and has caused 
many to wonder if there might be an NP shortage as well. This writer thinks the masters level NP 
is the best mechanism for trying to meet the coming demand in the short term, while at the same 
time, not completely exhausting the dwindling numbers of nurse educators needed to train and 
educate nurses of all degree levels.
Implications for Health Policy
It is clear, U.S. health policy with regard to mental health parity needs to progress to the 
point where there is no lack of parity between medical illness and mental illness. This writer is 
fully convinced that the longstanding practice of ascribing less value, less importance—and 
therefore, less care—to mental illness and addiction disorders has helped make mental illness 
stigma far worse and more entrenched than it might have been in an enlighten, educated society. 
A recent report states, approximately 70 million Americans experienced some form of mental 
illness in 2010. It further states, for about 17 million Americans the illness was severe enough to 
interfere with daily life activities such as school, work, and family (Conley, 2012). Each of those 
70 million Americans is intimately connected to at least one or two other Americans. Clearly, 
this issue affects all Americans. The report goes on to say mental illness and addictive illnesses 
are widespread in American Society across all socioeconomic lines.
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Very often, persons with SMI may have comorbid medical conditions such as high blood 
pressure, diabetes, cardiac disease, cancers, or other medical disease. Yet, only a small 
percentage of those with a mental illness actually seek out care, due to the walls of stigma put up 
by governments and insurance companies (Friedman, 2012). It makes no rational sense to argue 
for insuring wellness for the body, while at the same time, deny insuring wellness for the mind. 
Health care policies should advocate establishing full parity of illnesses in the U.S. It would be 
more than naive to think that full parity would immediately stamp out stigma or erase the deep 
emotional scars caused by it; however, it is more than reasonable to desire the eradication of a 
disease that has only harmed mankind.
Summary /Conclusions
Adherence and non-adherence behaviors fluctuate and should be considered part of the 
illness and therefore clinicians should seek to make managing it a learning experience for the 
patient (Weiden, 2007). He states, clinicians need to thoroughly assess each patient’s behavior 
and attitude with regard to medication adherence in order gain meaningful insight of where the 
patient stands. He goes on to say, clinicians should fully incorporate medication adherence into 
the psycho-educational process. The most critical assessment is to seek to know the patient’s 
core belief about medication, for as Weiden (2007) so emphatically puts it, “Perception is reality 
where patient beliefs about medication are concerned” (p. 17).
Provision 8, of the Code of Ethics for Nurses states “The nurse collaborates with other 
health professionals and the public in promoting community, national, and international efforts to 
meet health needs” (ANA, 2012). This statement speaks to the commitment of the nursing 
profession to strive to bring humane, compassionate care and advocacy to people across the 
expanse of the earth. This is also the personal conviction of this writer. People can change; but
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sometimes, they need a hand of assistance, words of direction, or a listening ear to better see the 
way they show go. Medication non-adherence is a persistent blight, not just in the clinical world 
of inpatient and outpatient mental health care, but even more so at the home front. Home is 
where people who live with, love, and care for individuals with SMI, struggle with the 
consequences of non-adherence every day. To have adherence to sound practices that promote 
wellness and wholeness on one’s side is to hold the power of recovery in one’s grasp. As 
clinicians and care providers, we must up our game, reinvigorate our resolve, reinvent our 
strategies, and remind ourselves that the only way to help patients with SMI and their families to 
lay claim to practical, realistic, achievable expectations for adherence, is through strong alliances 
and effective collaboration across the disciplines. Throughout history, it has always taken the 
entire village to make home strong, safe, and secure for everyone.
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a d h eren ce
P h arm acy  
reco rd s  use to  
m easu re  
p o ssess io n  
ratios
L o g is tic
R eg ress io n
m o d els
R esu lts  very  
s im ila r  o th er 
stud ies. F in d in g  
a rg u e  fo r new  
ap p ro ach es , 
an d  fu rth er 
stu d y
S how s 
n o n ad h eren c  
is  m u lti­
d e te rm in an t.
R oe  2 009
P s y c h i a t r i c  
R e h a b  
J o u r n a l  33
( i )
none Sem i-
s tru c tu red
in te rv iew
L evel C
n = 7  a d u lts  w ith  
SM I
fo u r  w o m en , 3 
m en
N A Q u a lita tiv e  
an a ly s is  to  
a sse ss  perso n a l 
m ean in g  o f  
tak in g  an d  
ch o o s in g  to  
stop
Q u a lita tiv e  
an a ly sis , 
th em a tic  
co n ten t 
u s in g  c ro ss  
c a se  an a ly sis
N arra tiv es  o f  
th e  p ro ce ss  o f  
h o w  an d  w h y  
one  d e c id e s  to  
s to p  tak in g  
m eds. V ery  
lim ited
g e n e ra lizab ility
P ro m o tes  
un d ers tan d i 
n g  o f  
p a tie n t’s  
p e rsp ec tiv e  
o f  p e rso n a l 
s id e  e ffec ts  
o f  tak in g  
m ed s and  
the  in n er 
strugg le.
V an D orn  
2010
P s y c h i a t r i c  
S e r v i c e  6 1  
( 1 0 ) ,  982 -8 7
R e tro sp ec tiv e  
an a ly s is  o f  
e ffe c t o f  
in v o lu n ta ry  
ou tp t tx  on  
m ed ica tio n
N = 3 5 7 6  S M I Invol tx  6  L o o k ed  a t M PR  
p a tien ts  o n  invo l m os o r  less  b e fo re  a n d  a fte r  
o u tp t tx  an d  o n  p e rio d s  o f  invol 
N Y  m ed ica id  Invo l tx  m o re  o u tp t tx 
ro lls  from  1999- than  6  m o s 
2 007
M P R , M P R  in creased  
M u ltiv a riab l w ith  both  
e  an a ly s is  v a riab le s , 
L o n g e r &  
h ig h er M PR  
w /lo n g er
T h e se  a re  
so m e  o f  the  
f irs t resu lts  
o f  th is  k ind  
o f  study. 
S h o w
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p o ssess io n  
ra te s  (M P R ) 
and
h o sp ita liza tio n
afte r
c o m m itm en t
re leased
L evel C
p erio d s  o f  
in v o lu n  tx
p ro m ise  o f  
inv o l ou tp t 
tx  h av in g  
p o s itiv e  
e ffec t in 
red u c in g  
ho sp ita liza ti 
on  &
p ro m o tin g  
tx  a d h e ren ce
V ellig an
(2 0 0 9 )
J  C l i n i c a l  
P s y c h i a t r y  
7 0  S u p p  4
N A E x p ert
c o n cen su s
gu id elin es
L evel D
4 1 /4 8  ex p e rts  
resp o n d ed  to  
su rv e y  39 
q u e s tio n s  w / 521 
O p tio n s  on  
fac to rs  o f  
adherence . 
S u rv ey s 
resp o n ses  
an a ly z e d  by  
in te rn a tio n a l 
pane l o f  7  e d ito rs
N A N A M an y
stu d ies
tes tin g
v a rio u s
in te rv en tio n s
rev iew ed
N o n ad h eren ce  
is  m u lti­
de te rm in an t 
an d  w ill req u ire  
v a rio u s  
in te rv en tio n s  
an d  m ust 
in clu d e  v a rio u s  
a lliances . 
G u id e lin es  
d ev e lo p e d  from  
su rv ey  
co n cen su s
V ery  usefu l 
ac ro ss  
c lin ica l 
d isc ip lin es  
to  th in k  
a b o u t n ew  
in te rv en tio n  
an d  s tu d ies  
to  te s t them .
V elligan
2 006
S ch izo p h ren  
B u lle tin , 32 
(4 ), 724-42
R ev iew  o f  
lite ra tu re
L ooked  at 
s tu d ies  to  d raw  
c o n cen su s  on  
d efin itio n  &  
a ssessem en t o f  
ad h e re ren ce  & 
P red ic to rs  o f  
n o n -ad h e ren ce  
w ith  a  po p
L evel A
n=161 v arious 
ty p es  o f  stu d ies , 
o v e r  th ree  
d ecad es  
a d h e re n c e  to 
m ed ica tio n  in 
sc h izo p h ren ia  
p a tie n ts
N A N A L o o g ed  and  
c o m p ared  
161 s tu d ies  
an d  th e ir  
a p p ro ach  to  
assess in g  
an d  d e fin in g  
ad h e ren ce
S u g g estio n s  
m ad e  to  
ad v an ce  the 
u n d e rs tan d in g  
p red ic to rs  o f  
a d h e ren ce  and 
to  d ev e lo p in g  
In te rv en tio n s  to 
im prove  
a d h e ren ce  to  
m ed ica tio n
V ery  usefu l 
acro ss  
c lin ica l 
d isc ip lin es  
to  th ink  
ab o u t new  
in te rv en tio n  
an d  s tu d ies  
to  te s t them
P ra tt (2 0 0 6 ) 
P s y c h i a t r i c  
R e h a b  J ,  2 9  
( 4 ) ,  2 9 9 -3 1 0
In ten siv e  case  
m gt
in te rv en tio n
ap p ro ach
R C T  lo o k in g  at 
M ed ica tio n  (all 
m ed s)
n o n ad h eren ce  
in o ld e r  p eo p le  
w / S M I, ac ro ss  
v a rio u s  
ad h e ren ce  
m easu rem en ts , 
an d  o th e r  
facto rs
L evel B
S tu d y  c o n d u c ted  
o v e r  12 m o s 
n =  72  S M I 
p a tien ts  o v e r  50 
y rs  o ld  rece iv in g  
c o m m u n ity  
m en ta l health  
se rv ices  a t  3 
ce n te rs  in N ew  
E n g lan d  a re a  o f  
U S
3 tx  g rps v s  1 
U su a l c a re  grp  
5 /1 5 /9  v s  43
T h e  tx  g rps
re c ’d
d iffe ren t
lev e ls  o f
m ed ica tio n
su p e rv is io n
P ill co u n ts ,
se lf-rep o rts ,
in fo rm an t
rep o rts ,
m ed ica tio n
a ttitu d e  sca le s
A lso  m easu red  
D em o g rap h ics, 
fu n ctio n al sk ill, 
e n v iro n m en ta l, 
co g n itiv e , &  
c lin ica l fac to rs
V ery  few  
s tu d ies  o f  th is  
ty p e  done. 
L ittle  v aria tio n  
b e tw een  
ad h e ren ce  
m easu res , se lf- 
rep o rts  ten d  to 
o v e restim a te  
ad h e ren ce  
M u ltip le  
fac to rs  affec t 
adh e ren ce .
M o re
su p e rv is io n  
w a s  re la te d  to  
b e tte r  a ttitu d es  
ab o u t 
ad h e ren ce ,
U sefu l
c o n c lu sio n s,
O b jec tiv e
m easu res
sh o u ld  be
u sed  to
eva lua te
ad h e ren ce ;
p a tien ts
b en efit from
sk ills
tra in in g  in
ad h e ren ce
stra teg ie s
S a jatov ic  
(2 0 0 6 ) 
P s y c h i a t r i c  
S e r v i c e s  5 7  
(1 )5 6 -6 2
N A C ro ss-sec tio n a l 
an a ly sis  o f  p t- 
p ro v id e r 
rea ltio n sh ip s ,
Pt
c h a rac te risr ics , 
and  p t b a rrie rs  
re la ted  to  se lf- 
rep o rt tx  
ad h e ren ce  
L evel C
D ept o f  V et 
A ffa irs  
A d h eren t grp  
n = l  13 &  
n o n ad h eren t grp 
n=71
V ets  w /  b ip o la r  
d iso rd e r
N A C hi sq u a re  tes ts  
&  p o o led  T  
tes ts  to  com pare  
d iffe ren ces  
b e tw n  th e  tw o  
g rps
A d h eren t grp 
w e re  less  like ly  
to  h ave  
su b stan ce  
issu es; an d  had 
b e tte r  f inancial 
su p p o rt
S tu d y  is
lim ited  in
several
w ay s, but
d o es
h igh ligh t
h ow
substance  
use  a s  m ajo r 
b a rrie r  to  
ad h e ren ce
V ree lan d  
(2 0 0 6 ) 
P s y c h i a t r i c  
S e r v i c e s  
57 (6 ) 822- 
28
N A R C T
“T eam
S o lu tio n s”
in te rv en tio n
P sy ch ed u ca tio n
2 4  w k s  vs
usua l trea tm en t
L evel B
n = 7 1 S M I p ts 
in partia l 
p ro g ram s
7 1 /5 5 0  p t 
v o lu n te e re d  fo r 
study
S tru c tu red
psy ch o ed u ca t
vs usual 
trea tm en t
M easu red  
q u a lity  o f  
k n o w led g e , 
L o o k ed  for 
im p ro v e  in 
sy m p to m s &  
fu n ctio n in g
L in ear
random
c o effic ien t
reg ress io n
m o d el; tx
co m p lian c
in te rv iew
(T C I), P anss,
C G I and
m an y  o th e r
m etric s
S ig n ifican t 
k n o w led g e  t ,  
no  ch a n g e  in 
sy p tm , o r 
fu n c tio n in g ,
S h o rt t im e
fram e
lim ita tio n ,
L ite ra tu re
sh o w  that
p sy c h o  ed
w /o u t
b eh av io ra l
and
su p p o rtiv e  
se rv ice  is 
in effec tiv e  
in a lte rin g  




OBLEM IS EPIDEMIC IN
20% to 30 % o f  clients 
with schizophrenia never 
even begin treatment upon 
being discharged from the 
hospital; 14% to 32% drift 
away from treatment 
within 3 months, and 
between 66% to 72% have 
completely discontinued 
compliance within 2 years 
(C ooket al.s 2008).
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N o n a d l t ®
We C«flKflSM |
In 2002, the total annual 
cost burden of serious 
mental illness in the US 





incarceration, and early 
mortality): 100 billion for 
health care expenditures; 
193 billion in estimated 
loss of earnings; and 24 




This treatise proposes 
to investigate the 
causes of medication, 
treatment non­
adherence in patients 
with serious mental 
illness (SMI)
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Research shows that treatment 
non-adherence is strongly 
associated with an increased risk 
for hospitalization (Corrigan, 
2002; Langetal., 2010).
The vast majority of psychiatric - 
mental heahn inpatients require 
re-hospitalization within two 
years of their previous inpatient 
admission, due to relapse, 
secondary to failure take 
prescribed medications 
(Vuckovich, 2010).
Serious mental Alness occurs m 
all populations and cultures 
across the lifespan
Unlike periodic somatic illness 
or disease, which might impair 
or disable a specific bodily 
function or set ofrelated 
functions, SMI has the potential 
to cast a very broad web of 
chronic impairment and 
dysfunction over all dimensional 
aspects of the individual person. 
VacaroHs and Halter state that 
SMI tends to be “recurrent or 
chronic” (2010, p. 678).
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F LITERATURE
The 18 studies selected 
for review, investigatec 
variety o f  interventi 
aimed at promoting 
enhancing adherence to 
psychotropic medication 
in populations with SMI
MET H U
^  tndanger« .
and lent him thm
■■M re -se a rch ’ ri'sa fl
\p\urall 1 soriou 
discover new tag 
research inj, 
s t u d e r  
tlat
fih* >•«*'
t n iv n a la a
, o n>*oMj
Sn»BvJorm »«
n literary docu, 
hed between the 
002-2012 were 
ising the AACN's 
»idence leveling system. 
The 18 studies were 
examined to  better 
understand what is known 
and not known about the 
challenge we face in trying 
to effect recovery and to 
prevent relapse of mental 
illness in the United States.
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Appendix A lists 18 studie
selected for review of
evidence related to 
adherence behaviors. It 
compares the type study 
the criteria for defining 
adherence, the methodT for 
assessing adherence non 
adherence, the sample size, 
the demographics o f the 
sample, and the types o f 
treatment intervention used 
in the study (if applicable).
Studies
m ca-* • *cr - a t - x r
Causal ar* t-su icc '.o- :s
Various types of studies, 
using different 
interventions, affirmed 
there are strategies and
interventions which can 
be used in helping to 
promote medication
adherence
However, to date, the 
literature does not show 
there to be a single, 
simple, intervention that 
is effective. The evidence 




various combinations of 
interventions is the best 




Despite the tremendous 
advancement and 
availability of evidence 
based psychosocial 
therapies and an 




adherence remains a 
monolithic impediment to 
recovery (Lehneretal., 




tr eatment non- 
adherence among 
patients with SMI can 
and do lead to very 
grave consequences 
on many levels 








process that is 
embedded in the core 



















interventions is the 
best strategy, but 
not a guarantee.
■
Nursing can use this 
knowledge to 
col laboratively work 
with patients, their 
families, and other 
health care team 
members to devise 
approaches to facilitate 
recovery and 
understanding of the 
role of medication 
adherence in recovery 
maintenance.
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Adherence and non-adherence As clinicians and care 
behaviors fluctuate and should providers we must up on 
be considered part of the game, reinvigorate our
illness and therefore clinicians
should seek to make strategies, and remind
managing it a learning
experience for the patient help patients with SMI and
(Weiden, 2007). their families to lav claim to
practical, realistic, achievable 
expectations for adherence, is 
through strong alliances and 
effective collaboration across 
the disciplines
Medication Adherence: To Have Is 
To Hold
Re c o v e r y  
Regins  
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ie»r^»: idiwKz »: î mc:M̂ caoc TVou^Au^o/
.1/rafirf C* * . .'4(12* S41W
CoflBfM. P W. (20QC) .U S p rix  r i  w liM  : !T»42t>x; b4U ">x:*:-5s
Jer*~-x: c/.U t fk*Li< ;/< !). 243-234 DOI10 300 09555230020023533 
la * . T JL (DOS) AttttMflf 2»o»ooff>: »*» of rmr.ti Coaa Jk
cfFsyoum  ̂ .»*.*<$>.m  doi »11*5*?j> 9 coos os®:*:«
L c ^ K .M e m .' L .K o a J  X.. Im  S .S is sa ..V . ^ r-sa .C .D a c a . J ..M a c c  .* 
(2010) Mod ao:< «£w~c;io3tnp:'ii30x jtoc«£* f-*sac*a ■R'iSb ;i-. ::c^ i 
*» * o3S M b p ^ d rt»a  *.’(12x1259 5c-.
10ir5**»pa.51  1 :  1139
L*acor. X. Eoyfca C. Cobott. 12. E*:*>rr. 12. Mx‘-*t M. l:m x. X. dr Voianr-i. D (200*>
C’̂ s o k ' : j 9 * r* t t  aC<o»r.2X£tS varo-ij - a c a : c < x u  A o f s o r a c o x a
REFERENCES
Varcarols.B. <5rH*5»r. P (Ida ) (2010) -ut^J J
tu-jz*- 4;; 'c« * (M o d  t Se Lo-«x MO Solder; Shove*
Vd%M, D . m * .  P. M . 3 s o s . . C*sp»e»t D . Hoax X.. &DoAwty:: - 2039)
The *r :ooaea*a f^ ie k e  >»w  A5b&r*.c*p «:>'. arrs e  psieoa —A  i » c - i  tod 
p M a»« 'rasa! i!beu JVt Junta! cfC±*ut*l “3% y l 4.1-45
Vdkfan.D. ^eid«i P J s t n ;  M . Sws. .*. D . Xoax X . & Do±om:'
(2010b) &r i55??*a-.-? aBaraoeaprobSan «e c*s9*3****ft iar>na aad
p^ratee: Keconm adicsi &M:de « p r  mcmcim rsadekm
Jo*”**:*'P* * * * * * .P ' tu m  J#(3*305-324 
DOI 10 109“ 01 pra 0000315525 95552 aO
V alor id , P (2010) Conylgpoa •■*r»a «  a*r>oa a&5 p*oe j» k maeu: C « n
V*u«S £:>**. ;r<3x ““-53 DOI 10 11*“ >959*3300933204*
” 's Jr. P >30*; V td e sx d iu  xd tddrsa<ac| adSerx a  mam *c i : i c  j^hratz Fror. 
!b®r:» prxa a  I k  J*■****: c f Ous*-' P*ythm*y. S3 S^*: J4. 14-39
